Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences’ MyoVista October 19, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today […]
Oct 19, 2022 Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences’ MyoVista SOUTHLAKE, Texas, Oct. 19, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known […]
Southlake, Texas–(October 18, 2022) – Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS) (NASDAQ: HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that Andrew Simpson, Chairman and Chief Executive […]
Southlake, Texas, October 6, 2022, (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today announced that […]
NEW BRUNSWICK — Robert Wood Johnson University Hospital and Rutgers Robert Wood Johnson Medical School have teamed up to launch a new model for medical research and innovation called The Center for Innovation located on the hospital’s main campus in New Brunswick. The center was made possible via donor funding from the RWJ University Hospital […]
HeartSciences Pumps Life into Assessing Diastolic Dysfunction with New AI Patent » Dallas Innovates Southlake-based HeartSciences, which closed on a $6.375M IPO in June, applies AI-based technology to an ECG to detect cardiac dysfunction—one of the earliest signs of heart disease. The company says this can’t be diagnosed by current conventional ECGs, making its MyoVista Wavelet […]
Southlake-based HeartSciences, which closed on a $6.375M IPO in June, applies AI-based technology to an ECG to detect cardiac dysfunction—one of the earliest signs of heart disease. The company says this can’t be diagnosed by current conventional ECGs, making its MyoVista Wavelet ECG device a potential game changer. CEO Andrew Simpson says adding this diagnostic […]
Sep 20, 2022 Patent continues to strengthen and expand IP portfolio Southlake, Texas, Sept. 20, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness […]
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas, September 13, 2022 (GLOBE NEWSWIRE) – Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative […]
Andrew Simpson, HeartSciences Chairman and Chief Executive Officer presents at the H.C. Wainwright 24th Annual Global Investment Conference Webcast (September 12-14, 2022). View the full webcast via the following link: Journey (ct.events)
©2023. ™ Trademark of HeartSciences. Reg. US Pat. & TM off. All Rights Reserved.
MV-WBSTE-001 Rev B
wavECG and wavEKG are trademarks of HeartSciences.
